CervoMed Inc
CRVO
查看详细走势图
7.600USD
-0.300-3.80%
收盘 12/19, 16:00（美东）报价延迟15分钟
70.32M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-3.80%
5天
-10.06%
1月
-14.41%
6月
+10.95%
今年开始到现在
+224.79%
1年
+240.81%
查看详细走势图
TradingKey CervoMed Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
CervoMed Inc当前公司基本面数据相对非常健康，增长潜力较大。当前估值合理，在生物技术与医疗研究行业排名160/404位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价22.43。中期看，股价处于平稳状态。近一个月，市场表现较差，但公司基本面和技术面得分较高。目前股价在压力位和支撑位之间，可以做区间波段操作。
CervoMed Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
7
位分析师
买入
评级
22.429
目标均价
+155.16%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
CervoMed Inc亮点
亮点风险
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
业绩增长期
公司处于发展阶段，最新年度总收入9.74M美元
估值合理
公司最新PE估值-2.62，处于3年历史合理位
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值343.46K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.81
CervoMed Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
CervoMed Inc简介
CervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
公司代码CRVO
公司CervoMed Inc
CEOAlam (John J)
网址https://cervomed.com/
常见问题
CervoMed Inc(CRVO)的当前股价是多少？
CervoMed Inc(CRVO)的当前股价是 7.600。
CervoMed Inc的股票代码是什么？
CervoMed Inc的股票代码是CRVO。
CervoMed Inc股票的52周最高点是多少？
CervoMed Inc股票的52周最高点是16.940。
CervoMed Inc股票的52周最低点是多少？
CervoMed Inc股票的52周最低点是1.920。
CervoMed Inc的市值是多少？
CervoMed Inc的市值是70.32M。
CervoMed Inc的净利润是多少？
CervoMed Inc的净利润为-16.29M。
现在CervoMed Inc(CRVO)的股票是买入、持有还是卖出？
根据分析师评级，CervoMed Inc(CRVO)的总体评级为买入，目标价格为22.429。
CervoMed Inc(CRVO)股票的每股收益（EPS TTM）是多少
CervoMed Inc(CRVO)股票的每股收益（EPS TTM）是-2.903。
相关品种
